Mesoblast presented 36-month follow-up results from a Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L (MPC-06-ID) in patients with chronic low back pain (CLBP) associated with degenerative disc disease (DDD). A single intra-discal injection of rexlemestrocelL+hyaluronic acid (HA) carrier resulted in a durable reduction in back pain lasting at least three years. The results were presented by Mesoblast Chief Executive Dr. Silviu Itescu at the 2022 Biotech Showcase event.
The multicenter, randomized, double-blind, placebo-controlled phase 3 trial enrolled 404 patients with chronic low back pain (> 6 months) associated with moderate radiographic degenerative changes of a disc.
Mesoblast reported positive data last year showing a single injection of MPC + HA resulted in significant and durable reductions in CLBP through 24 months across the entire evaluable study population (n=391) compared with placebo. The greatest pain reduction was observed in the pre-specified population with CLBP of shorter duration than the study median of 68 months (n=194). Data presented at the showcase confirm these results, suggesting that greatest benefits may be seen when the therapy...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).